<DOC>
	<DOCNO>NCT02497313</DOCNO>
	<brief_summary>Accumulating evidence suggest bile acid intestine may constitute essential component complex mechanism regulate gut hormone secretion glucose homeostasis . Thus , likely modification enterohepatic circulation bile acid lead change gut hormone secretion consequently affect glucose homeostasis . The current study human interventional randomize control cross-over study include four study day participant . Metformin apply tool reduce bile acid reuptake small intestine ; thereby increase bile acid concentration distal part gut GLP-1-secreting L cell abundant . Interestingly , metformin show reduce active reabsorption bile acid ileum cause increase faecal elimination bile acid . Clinical data suggest metformin cause increase postprandial secretion GLP-1 human include patient type 2 diabetes . Intravenous infusion cholecystokinin use elicit gallbladder contraction empty . The aim examine ( ) modification bile acid reabsorption influence postprandial glucagon-like peptide-1 ( GLP-1 ) secretion glucose homeostasis patient type 2 diabetes . The investigator hypothesize high luminal concentration bile acid distal gut elicit change gut hormone secretion . The current study help clarify hypothesis improve general understand association bile acid circulation signalling , gut hormone secretion glucose metabolism .</brief_summary>
	<brief_title>Effect Metformin Cholecystokinin-mediated Gallbladder Emptying GLP-1 Secretion Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Cholecystokinin</mesh_term>
	<criteria>Type 2 diabetes least 3 month ( diagnose accord criterion World Health Organization ( WHO ) ) Men postmenopausal woman Metformin apply antidiabetic drug Caucasian ethnicity Normal haemoglobin BMI &gt; 23 kg/m2 &lt; 35 kg/m2 Informed write consent Liver disease ( alanine aminotransferase ( ALAT ) and/or serum aspartate aminotransferase ( ASAT ) &gt; 2 time normal value ) history hepatobiliary disorder Gastrointestinal disease , previous intestinal resection , cholecystectomy major intraabdominal surgery Nephropathy ( serum creatinine &gt; 150 ÂµM and/or albuminuria ) Hypo hyperthyroidism Hypo hypercalcaemia Hypo hyperphosphataemia Active recent malignant disease Treatment medicine pause 12 hour Treatment oral anticoagulant Any treatment condition require acute subacute medical surgical intervention Any condition consider incompatible participation investigator</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>